𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Activated platelets as a possible early marker to predict clinical efficacy of leukocytapheresis in severe ulcerative colitis patients

✍ Scribed by Ken Fukunaga; Yoshihiro Fukuda; Yoko Yokoyama; Kunio Ohnishi; Takeshi Kusaka; Tadashi Kosaka; Nobuyuki Hida; Yoshio Ohda; Hiroto Miwa; Takayuki Matsumoto

Publisher
Springer Japan
Year
2006
Tongue
English
Weight
242 KB
Volume
41
Category
Article
ISSN
0944-1174

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety and tolerability of a modified fi
Safety and tolerability of a modified filter-type device for leukocytapheresis using ACD-A as anticoagulant in patients with mild to moderately active ulcerative colitis. Results of a pilot study
✍ Vladislaw Muratov; Joachim Lundahl; Aleksandra Mandic-Havelka; Kerstin Elvin; Åk 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 117 KB

## Abstract Cellsorba™ is a medical device for leukocytapheresis (LCAP) treatment of ulcerative colitis (UC). Cellsorba™ EX Global type has been developed from Cellsorba E for intended use with ACD‐A as anticoagulant. We evaluated safety and efficacy of the modified Cellsorba using ACD‐A in a pilot